Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

77.40 -0.19 (-0.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,591,711
Open 78.48
Bid (Size) 77.25 (1)
Ask (Size) 77.59 (5)
Prev. Close 77.59
Today's Range 76.06 - 78.52
52wk Range 62.55 - 170.47
Shares Outstanding 384,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Wellness In Your Personal Life Unleashes Productivity At Work
Our world is obsessed with individual productivity. 
Via Investor's Business Daily

Performance

YTD
-31.20%
-31.20%
1 Month
-35.08%
-35.08%
3 Month
-45.70%
-45.70%
6 Month
-18.58%
-18.58%
1 Year
-31.55%
-31.55%

More News

Read More
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Via Benzinga
Exposures COVID-19
Shareholder Rights Law Firm Robbins LLP Urges Moderna, Inc. Stockholders to Seek Counsel for the MRNA Class Action
From Robbins LLP
Via GlobeNewswire
Moderna Unusual Options Activity
Via Benzinga
This Moderna Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential
Via Benzinga
INVESTOR ALERT:   Shareholder Class Action Lawsuit Filed Against Moderna, Inc. (NASDAQ: MRNA); Investors with Losses Encouraged to Discuss Their Options with Counsel
From DiCello Levitt LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today
Via Benzinga
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
Via Benzinga
Exposures COVID-19
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Snowflake, JD.com And Temu Parent PDD Are Among Top 8 Large Cap Losers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?
Via Benzinga
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Moderna to Host Investor Event - R&D Day and Business Updates
Via ACCESSWIRE
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Via ACCESSWIRE
Moderna's Options: A Look at What the Big Money is Thinking
Via Benzinga
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
The Stock Market Isn't Rocking This Month But The S&P 500 Is Headed For Its Best August In 3 Years
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Europe Approves Moderna's RSV Vaccine For Adults 60 And Over
Via Benzinga
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
Via ACCESSWIRE
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
Via ACCESSWIRE
Nasdaq 100 Slumps 1.6% As Traders Turn Cautious Ahead Of Powell's Jackson Hole Address
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
Via Benzinga
Exposures COVID-19 Product Safety
Stocks Move Lower As Rate Cut Enthusiasm Fades
Via Talk Markets
Topics Economy
Exposures Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.